Cigna Group $CI Shares Bought by Associated Banc Corp

Associated Banc Corp grew its holdings in shares of Cigna Group (NYSE:CI) by 0.3% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 116,837 shares of the health services provider’s stock after purchasing an additional 396 shares during the quarter. Cigna Group makes up about 1.1% of Associated Banc Corp’s investment portfolio, making the stock its 25th biggest position. Associated Banc Corp’s holdings in Cigna Group were worth $38,624,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in CI. Advisors Asset Management Inc. lifted its position in Cigna Group by 4.6% during the second quarter. Advisors Asset Management Inc. now owns 6,419 shares of the health services provider’s stock worth $2,122,000 after buying an additional 282 shares during the period. Laurel Wealth Advisors LLC increased its stake in shares of Cigna Group by 32,958.6% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 19,174 shares of the health services provider’s stock valued at $6,339,000 after acquiring an additional 19,116 shares during the last quarter. NDVR Inc. increased its stake in shares of Cigna Group by 5.0% during the 2nd quarter. NDVR Inc. now owns 779 shares of the health services provider’s stock valued at $258,000 after acquiring an additional 37 shares during the last quarter. Insigneo Advisory Services LLC lifted its holdings in shares of Cigna Group by 10.5% during the 2nd quarter. Insigneo Advisory Services LLC now owns 1,553 shares of the health services provider’s stock worth $513,000 after acquiring an additional 147 shares during the period. Finally, CreativeOne Wealth LLC boosted its position in shares of Cigna Group by 49.3% in the second quarter. CreativeOne Wealth LLC now owns 1,745 shares of the health services provider’s stock worth $577,000 after acquiring an additional 576 shares during the last quarter. Hedge funds and other institutional investors own 86.99% of the company’s stock.

Insider Transactions at Cigna Group

In related news, insider Brian C. Evanko sold 5,368 shares of the business’s stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $300.00, for a total value of $1,610,400.00. Following the transaction, the insider owned 51,182 shares in the company, valued at approximately $15,354,600. The trade was a 9.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO David Cordani purchased 4,134 shares of Cigna Group stock in a transaction that occurred on Monday, November 3rd. The stock was acquired at an average cost of $241.88 per share, with a total value of $999,931.92. Following the acquisition, the chief executive officer directly owned 157,935 shares of the company’s stock, valued at $38,201,317.80. The trade was a 2.69% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 0.70% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on CI shares. Wolfe Research dropped their price target on shares of Cigna Group from $345.00 to $325.00 and set an “outperform” rating for the company in a research report on Wednesday, October 15th. Morgan Stanley restated an “overweight” rating and set a $355.00 price objective on shares of Cigna Group in a report on Friday, October 31st. Raymond James Financial reiterated a “strong-buy” rating on shares of Cigna Group in a report on Monday, November 3rd. Sanford C. Bernstein lowered their price target on Cigna Group from $346.00 to $294.00 and set a “market perform” rating for the company in a research report on Wednesday, November 12th. Finally, TD Cowen cut their price objective on Cigna Group from $387.00 to $333.00 and set a “buy” rating on the stock in a report on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $334.05.

Cigna Group Stock Performance

Cigna Group stock opened at $272.00 on Tuesday. The firm has a market capitalization of $72.66 billion, a PE ratio of 14.85, a price-to-earnings-growth ratio of 0.88 and a beta of 0.44. Cigna Group has a one year low of $239.51 and a one year high of $350.00. The stock’s 50 day moving average price is $286.23 and its 200 day moving average price is $298.26. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.71 and a current ratio of 0.71.

Cigna Group (NYSE:CI) last posted its quarterly earnings data on Thursday, October 30th. The health services provider reported $7.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.64 by $0.19. Cigna Group had a net margin of 1.92% and a return on equity of 18.80%. The company had revenue of $69.57 billion for the quarter, compared to analyst estimates of $66.40 billion. During the same quarter last year, the firm posted $7.51 earnings per share. The business’s quarterly revenue was up 9.5% on a year-over-year basis. Cigna Group has set its FY 2025 guidance at 29.600- EPS. As a group, sell-side analysts expect that Cigna Group will post 29.77 EPS for the current fiscal year.

Cigna Group Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 18th. Shareholders of record on Thursday, December 4th will be issued a $1.51 dividend. The ex-dividend date is Thursday, December 4th. This represents a $6.04 dividend on an annualized basis and a yield of 2.2%. Cigna Group’s payout ratio is currently 26.64%.

Cigna Group Profile

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers.